Results 1 to 10 of about 119,370 (191)
Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations [PDF]
Haematologica, 2014 Somatic insertions/deletions in the calreticulin gene have recently been discovered to be causative alterations in myeloproliferative neoplasms. A combination of qualitative and quantitative allele-specific polymerase chain reaction, fragment-sizing ...
Hajnalka Andrikovics +13 more
doaj +3 more sources
Machine learning-based prediction of response to Janus kinase inhibitors in patients with rheumatoid arthritis using clinical data [PDF]
Frontiers in ImmunologyObjectiveRheumatoid arthritis (RA) is a chronic inflammatory disease with considerable heterogeneity in treatment response, leaving many patients unable to achieve remission or low disease activity. We aimed to develop a machine learning model to predict
Yeo-Jin Lee +10 more
doaj +2 more sources
Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives [PDF]
Psoriasis: Targets and Therapy, 2019 Karen Ly,1 Kristen M Beck,1 Mary P Smith,1 Ana-Maria Orbai,2 Wilson Liao11Department of Dermatology, University of California San Francisco, San Francisco, CA, USA; 2Division of Rheumatology, Johns Hopkins University, Baltimore, MD, USACorrespondence ...
Ly K +4 more
doaj +2 more sources
Janus kinase inhibitors - their current applications and future prospects [PDF]
Farmacja Polska, 2022 Janus kinase inhibitors are a group of drugs that provide an alternative to conventional therapy for numerous diseases. The most studied drug of this group is tofacitinib.
Natalia Wierzbowska +4 more
doaj +1 more source
Itch and Janus Kinase Inhibitors
Acta Dermato-Venereologica, 2023 Itch is a common skin symptom, with complex aetiology and pathogenesis. It is mediated by 2 pathways, the histaminergic and non-histaminergic pathways.
Yujin Han +4 more
doaj +1 more source
JAK3 as an emerging target for topical treatment of inflammatory skin diseases [PDF]
, 2016 The recent interest and elucidation of the JAK/STAT signaling pathway created new targets for the treatment of inflammatory skin diseases (ISDs). JAK inhibitors in oral and topical formulations have shown beneficial results in psoriasis and alopecia ...
Alves de Medeiros, Ana +5 more
core +14 more sources
A JAK of all trades: how global phosphoproteomics reveal the Achilles heel of MPNs
Molecular & Cellular Oncology, 2021 While Janus-kinase (JAK)-inhibitors effectively reduce the inflammatory phenotype of myeloproliferative neoplasms (MPN), they do not affect disease burden or presence of the mutated clone to a major extent. Here, we show how Janus-kinase 2 (JAK2)-mutated
Tina M. Schnoeder +2 more
doaj +1 more source
Immunological Medicine, 2023 Recent studies have gradually elucidated the pathogenesis of inflammatory bowel disease; thus, the Janus kinase (JAK)-signal transducers and activators of transcription pathway are strongly involved in the pathophysiology of inflammatory bowel disease ...
Hiroshi Nakase
doaj +1 more source
Journal of the Scientific Society, 2023 Background: Coronavirus disease 2019 (COVID-19), it is an infectious respiratory disease caused by SARS corona virus 2 (SARS CoV-2). There are several reports of using JAK (Janus kinase)-inhibitors in persons with COVID-19 and the use of these decreased ...
Shankar Gharge +3 more
doaj +1 more source
Janus Kinase Inhibitors in the Treatment of Alopecia Areata
Prague Medical Report, 2023 Alopecia areata is a disease of autoimmune origin which causes non scarring hair loss. The extent of alopecia varies from a small patch to complete scalp and body hair loss, which can have huge psychosocial impact for those affected. Treatment modalities
Athanasios J. Stefanis
doaj +1 more source